Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-011504
Filing Date
2021-08-12
Accepted
2021-08-12 16:46:30
Documents
44
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q apre-20210630x10q.htm   iXBRL 10-Q 842506
2 EX-31.1 apre-20210630xex31d1.htm EX-31.1 9744
3 EX-31.2 apre-20210630xex31d2.htm EX-31.2 9735
4 EX-32.1 apre-20210630xex32d1.htm EX-32.1 6726
5 EX-32.2 apre-20210630xex32d2.htm EX-32.2 6719
  Complete submission text file 0001558370-21-011504.txt   2735474

Data Files

Seq Description Document Type Size
6 EX-101.SCH apre-20210630.xsd EX-101.SCH 20890
7 EX-101.CAL apre-20210630_cal.xml EX-101.CAL 29390
8 EX-101.DEF apre-20210630_def.xml EX-101.DEF 30113
9 EX-101.LAB apre-20210630_lab.xml EX-101.LAB 195408
10 EX-101.PRE apre-20210630_pre.xml EX-101.PRE 127240
11 EXTRACTED XBRL INSTANCE DOCUMENT apre-20210630x10q_htm.xml XML 317106
Mailing Address 535 BOYLSTON STREET BOSTON MA 02116
Business Address 535 BOYLSTON STREET BOSTON MA 02116 6095104718
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39069 | Film No.: 211168307
SIC: 2834 Pharmaceutical Preparations